Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


CSL joins gene therapy surge

Posted 15 October 2020

One of the first gene therapies to provide long-term benefits to patients with haemophilia B could launch as early as 2022, CSL CEO Paul Perreault has announced at the company's AGM.

Under a deal brokered with Dutch biotech uniQure in June this year, CSL has exclusive global rights to the new therapy which has the potential to offer long-term improvements with just one dose.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
How much to save the kid?
We paid a high price for our elderly so what about children
Special Report
Aust Covid Vaccine Tracker
UPDATES: Sanofi/GSK sign Statement of Intent with Gavi; Aust to import 3.8m vax doses
Approvals Action
Novartis' triplet inhaler ticked
First-in-class maintenance treatment of asthma